The Future of Biosimilars
Author(s) -
L El-Bakry
Publication year - 2017
Publication title -
international journal of drug delivery
Language(s) - English
Resource type - Journals
ISSN - 0975-0215
DOI - 10.5138/09750215.1930
Subject(s) - biosimilar , business , competition (biology) , quality (philosophy) , risk analysis (engineering) , industrial organization , marketing , medicine , ecology , philosophy , epistemology , biology
Biosimilars are to Biologic products what generic drugs are to chemical products, a more affordable solution to the increasing drug pricing without sacrificing the quality of the treatment.There is much debate in the health care industry as to whether Biosimilars will deliver on the same success achieved by the generic products, which can amount to up to 80% in some cases. It is my view though that Biosimilars provide a viable path to cost reduction, quality improvement and affordable accessibility to medication. In fact, the introduction of lower costs Biologics as intended by the Biosimilar market will force competition within the therapeutics treatment market that will both exertpricing pressure as well as inspire innovation in the entire ecosystem.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom